Thought Leadership

Our leading subject matter experts share their insightful analysis and points of view to help you stay abreast of industry trends

Current Events

Manufacturers and the Mental Health Crisis: How Data and Education Can Improve Patient Access

According to the National Institutes of Health (NIH), nearly one in five U.S. adults (approximately 52 million) live with some form of mental illness. Unfortunately, those struggling with a mental health disorder often aren’t getting the treatment they need, and when undertreated, can have considerable economic impact on national healthcare

PrEP Therapy Can End the HIV Epidemic, but Equitable Access Is Key

Amid a global pandemic that has been the foreground of thought and development in medicine the past two years, another epidemic has been lingering for decades: HIV and AIDS were first recorded in the early 1980s, and their presence has grown exponentially over the last 40 years. In that time,

FDA Updates to JAK Inhibitors: How Are Payers Reacting, and What Do Pharma Companies Need to Know?

After the FDA called for additional warning labels on anti-inflammatory drugs known as JAK inhibitors this September, pharma companies in the immunology space have been waiting with bated breath to see how payers will react to this news. Will insurers start requiring step-edits or prior authorization? Will payers alter their

What to Expect at This Year’s Asembia Specialty Pharmacy Summit

The COVID-19 pandemic has been an unrelenting trial—one that, in many ways, accelerated the pace of change in the life sciences industry. In the wake of breathtakingly fast novel vaccine development, an abrupt shift toward virtual care and a renewed focus on digital therapeutics, things look vastly different than they

For Payers, Determining Aduhelm Coverage Is a Waiting Game

This article was originally published in FierceHealthcare. While it has been over a month since the FDA announced its controversial decision to approve Biogen’s Alzheimer’s drug, Aduhelm, payers have been slow to make any decisions—and for good reason. While the excitement around the approval is undeniable given the long-overdue unmet